Navigation Links
Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
Date:7/15/2008

- Company Reports Favorable Phase 1 RX-3341 Results -

NEW HAVEN, Conn., July 15 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the initiation of a Phase 2 clinical trial for an intravenous form of antibiotic compound RX-3341 in the treatment of complicated skin and skin structure infections (cSSSIs). The safety and efficacy study will be conducted at 35 sites across the United States. As a precursor to this news the Company also announced positive results of a two-part Phase 1 study with the same candidate.

"We have made significant progress in advancing this next-generation broad spectrum antibiotic further toward clinical use," said Dr. Susan Froshauer, President and CEO of Rib-X. "We intend to rapidly move forward with the development of our IV dosage form to meet the need for a broad-spectrum antibiotic in the hospital setting, particularly one that is active against quinolone-resistant MRSA. We also hope to further progress our oral dosage form to ensure a greater diversity of use in the treatment of serious infections in a number of settings."

Phase 2 Study Design

This Phase 2 double-blind study (study RX-3341-201) will evaluate the safety and efficacy of RX-3341 at two different doses administered intravenously to hospitalized cSSSI patients every 12 hours for 5 to 14 days, as compared to tigecycline (Tygacil(TM)). The study's primary endpoint is the assessment of RX-3341 efficacy, safety and tolerability at the two different doses compared to that of tigecycline's standard dosing regimen. A secondary endpoint for the study is the assessment of clinical efficacy of RX-3341 compared to tigecycline in patients with cSSSIs caused by methicillin- resistant Staphylococcus aureus (MRSA).

Phase I Results

The two-part Phase 1 stud
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
2. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
3. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
4. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
5. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
6. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
7. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
8. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. Isis Pharmaceuticals Conference Call Notice
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Aethlon Medical, Inc. (OTCQB:AEMD), announced today that ... approximately $3.3 million at a price of $0.30 per ... focused investor. Each unit consists of one common share ... warrant. Each whole warrant entitles the holder to acquire ... a period of five years from closing.  ...
(Date:11/26/2014)... Texas , Nov. 26, 2014 ... today announced the completion of previously announced concurrent ... million.  After fees and estimated offering expenses, Lexicon ... the transactions.  The transactions consisted of: ... common stock, pursuant to a registration statement that ...
(Date:11/26/2014)... -- Investor-Edge has initiated coverage on the following ... PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... ), and Theravance Inc. (NASDAQ: THRX ). Free ... http://investor-edge.com/register . On Tuesday, November 25, 2014, the ... Industrial Average edged 0.02% lower, to finish the day at ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
(Date:11/28/2014)... 28, 2014 Dr. Andrew Campbell, one ... announced the expansion of Quintessa Aesthetic Center into a ... located at W307 N1497 Golf Road in Suite 200 ... Dr. Campbell, the new Delafield location will offer a ... patients, including: Botox, filler injectables , micro laser ...
(Date:11/28/2014)... 2014 The Alternative Health ... the past five years. The industry has been ... that are either alternative to conventional Western medicine ... industry analyst David Whytcross, “industry revenue has been ... private health insurance membership.” Meanwhile, improving economic conditions ...
(Date:11/28/2014)... News) -- Planning on seconds at Thanksgiving Day dinner ... known as gastroesophageal reflux disease (GERD) -- a few steps ... ear, nose and throat specialist at Lenox Hill Hospital in ... GERD on Thanksgiving: Pace yourself. Rather ... meals throughout the day. It,s also a good idea to ...
(Date:11/28/2014)... 28, 2014 An inventor and dental assistant ... a patient’s filling and it was almost impossible to reach. ... light," she said. , The patent-pending Access Light allows for ... to areas of the mouth, as well as avoids harm ... safety. Easy to use and clean, it also helps prevent ...
(Date:11/28/2014)... 2014 A newly released article ... of the influenza virus that will soon be spreading across ... The article begins with a brief explanation of what the ... reminds families that children under the age of 5, adults ... diseases, such as heart and lung diseases, asthma, or diabetes, ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Don't Let Chronic Heartburn Spoil Your Thanksgiving Feast 2Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2
... increase in Social Security Disability Insurance recipients; time-intensive process of receiving ... Allsup , ... Belleville, Ill. (Vocus) June 25, 2008 ... Insurance (SSDI) benefits continued to grow in 2007. This means ...
... The National Intelligence Council (NIC) has completed a new ... U.S. security in the next 20 years by causing ... over water and other resources in specific countries. The ... June 25, on the main findings. , ...
... are the workhorses of our cells. They help to digest ... and literally shape our body from top to toe. Proteins ... of enzymes, which are important in the creation of anything ... possibilities are virtually without limit. , To take advantage ...
... of venous thromboembolism, study finds , , WEDNESDAY, June 25 ... rivaroxaban helps prevent potentially fatal blood clots after hip ... of venous thromboembolism (VTE) is high after total hip ... leaves hospital. Current guidelines recommend patients receive a heparin-based ...
... Pharmavite, a leader in the,dietary ... consumer-centric,program, LearnSomethingAbout(TM), as a partner in ... consumer-oriented multimedia,program that seamlessly integrates into ... "LearnSomething shares similar goals with Pharmavite ...
... MedeFile,International, Inc. (OTC Bulletin Board: MDFI), a company ... announced,that a highly exclusive, membership only, resort community ... memberships and is offering,MedeFile,s full suite of products ... 1,400 members., Members who subscribe to MedeFile,s ...
Cached Medicine News:Health News:SSDI Recipients Ask: When Do I Get My Benefits? 2Health News:SSDI Recipients Ask: When Do I Get My Benefits? 3Health News:Climate change may challenge national security, classified report warns 2Health News:Climate change may challenge national security, classified report warns 3Health News:1 step closer to green chemistry and improved pharmaceuticals 2Health News:Oral Drug Helps Prevent Clotting After Hip Replacement 2Health News:Pharmavite Partners With LearnSomething, Inc. on Consumer Education Program, LearnSomethingAbout(TM) 2Health News:Exclusive Resort Community Looks to MedeFile to Provide Members With Access to Medical Records Anytime, Anywhere 2
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
... The Attain™ Deflectable Catheter - designed ... using a single catheter. Steerablility - Create ... procedure with a single, steerable guide catheter. ... desired shape to address each patient's unique ...
Attain LV Leads. Navigate minimally angled veins with little to moderate tortuosity....
... The Hancock® II bioprosthesis from ... years of proven clinical experience. ... the freedom from structural valve ... and mitral bioprostheses is substantially ...
Medicine Products: